Cytori Announces Top-Line 24- and 48-Week Results from the STAR Trial of Habeo(TM) Cell Therapy in Patients with Scleroderma

Stock Information for Cytori Therapeutics Inc

Loading

Please wait while we load your information from QuoteMedia.